Is it time to Buy before this week’s earning report Legend Biotech (NASDAQ:DADA)

0
176

Earnings results for Legend Biotech (NASDAQ:DADA)

Dada Nexus Limited is expected* to report earnings on 08/24/2020 after market close. The report will be for the fiscal Quarter ending Jun 2020.

Analyst Opinion on Legend Biotech (NASDAQ:DADA)

1 Wall Street analysts have issued ratings and price targets for Legend Biotech in the last 12 months. Their average twelve-month price target is $22.00, predicting that the stock has a possible downside of 24.81%. The high price target for DADA is $22.00 and the low price target for DADA is $22.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of “Hold.”

Legend Biotech has received a consensus rating of Hold. The company’s average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $22.00, Legend Biotech has a forecasted downside of 24.8% from its current price of $29.26. Legend Biotech has only been the subject of 1 research reports in the past 90 days.

Dividend Strength: Legend Biotech (NASDAQ:DADA)

Legend Biotech does not currently pay a dividend. Legend Biotech does not have a long track record of dividend growth.

Insiders buying/selling: Legend Biotech (NASDAQ:DADA)

In the past three months, Legend Biotech insiders have not sold or bought any company stock.

Earnings and Valuation of Legend Biotech (NASDAQ:DADA

Earnings for Legend Biotech are expected to grow in the coming year, from ($1.82) to ($0.98) per share.

More latest stories: here